“While prevailing treatment approaches only address the symptoms associated with narcolepsy type 1, we believe orexin agonists offer a disruptive approach, with the capacity to address the underlying pathology of the disorder."
The custom-built, 70,000 sq-ft building sits on a 7-acre campus located in the heart of the high technology corridor in St. Charles County.
An American Academy of Dental Sleep Medicine task force provides a consensus-based definition, as well as supported methods for measurement.
3B MaskFitter scans facial geometry to determine appropriate cushion size and narrow down mask type.
ChiliSleep and Ebb Therapeutics join forces. Ebb’s largest investor led a $37 million investment to accelerate the merged company’s growth.
SleepX's DreamIT is a wristband will include several sensors and a vibration motor that will operate with an intensity adapted to the user's reactions to accustom the user to sleep in the correct position using biofeedback.
The primary endpoint will be the frequency of cataplexy attacks. Other symptoms of narcolepsy as well as safety will also be assessed.
It is an update to the AASM’s 2010 guideline, which made recommendations for specific surgical procedures but did not address when to consider such options.
OptumRx will offer and administer standard pharmacy benefit coverage for members who choose to add the product to their formularies.